Insulin lispro - Sanofi

Drug Profile

Insulin lispro - Sanofi

Alternative Names: Insulin lispro Biosimilar - Sanofi; Insulin lispro Sanofi; SAR-342434

Latest Information Update: 04 Aug 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sanofi
  • Class Antihyperglycaemics; Insulins; Pancreatic hormones
  • Mechanism of Action Ornithine decarboxylase stimulants; Phosphokinase stimulants; Tyrosine aminotransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Registered Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 31 Jul 2017 Registered for Type-1 diabetes mellitus (In adults, In children) in European Union (SC)
  • 31 Jul 2017 Registered for Type-2 diabetes mellitus (In adults, In children) in European Union (SC)
  • 09 Jun 2017 Adverse events and efficacy data from a phase III SORELLA-2 trial in Type-2 diabetes mellitus presented at the 77th Annual Scientific Sessions of the American Diabetes Association (ADA-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top